Clinical Trial Update: JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating JAK inhibitors for solid tumor patients with dermatitis refractory to immune checkpoint inhibitor therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Checkpoint Inhibitor-induced Dermatitis

Drugs mentioned

• JAK inhibitors (Janus kinase inhibitors)

Snippet

Sponsor: Shixiu Wu | Conditions: Immune Checkpoint Inhibitor-Induced Dermatitis | Phase 2 | Status: NOT_YET_RECRUITING